Tildrakizumab candidates

Tildrakizumab (Ilumya), an Interleukin-23 (IL-23) inhibitor, can provide long-term improvement, even in higher-risk psoriasis patients. Tildrakizumab is a type of drug called a monoclonal antibody. It is a protein that specifically treats certain parts of your immune system. Unlike many other psoriasis treatments, tildrakizumab can be used in higher-risk populations, such as in the elderly or those with psoriasis in addition to other health conditions like inflammatory bowel disease (IBD) or psoriatic arthritis.

Next Video

Tildrakizumab effectiveness related to trial results

Long-term use of interleukin-23 (IL-23) psoriasis therapies
This physician-led video initiative explores community experience with the long-term use and effect of interleukin-23 (IL-23) psoriasis therapies.